A 48-year-old woman with stage IIIC epithelial ovarian cancer (serous histology) has completed 6 cycles of neoadjuvant chemotherapy (carboplatin + paclitaxel) and achieved a clinical complete response. She is now scheduled for interval cytoreductive surgery. Intraoperatively, the surgeon finds minimal residual disease and achieves R0 resection. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has achieved optimal cytoreduction (R0 resection) after neoadjuvant chemotherapy for stage IIIC ovarian cancer. The question addresses adjuvant therapy after interval debulking surgery. ## Current Standard of Care **Key Point:** After optimal cytoreduction in advanced ovarian cancer, the standard adjuvant regimen is: 1. **3 additional cycles of platinum-based chemotherapy** (to complete 6 total cycles) 2. **Bevacizumab maintenance therapy** until disease progression or unacceptable toxicity This approach is based on multiple high-level trials (GOG-0218, ICON7, SOLO-1, PAOLA-1). ## Evidence-Based Rationale | Trial | Population | Intervention | Outcome | |-------|-----------|--------------|----------| | GOG-0218 | Stage III/IV, post-chemo | Bevacizumab + chemo + maintenance | ↑ PFS (14.1 vs 10.7 mo) | | ICON7 | Stage III/IV | Bevacizumab + chemo + maintenance | ↑ PFS (19 vs 17.3 mo) | | PAOLA-1 | BRCA-mutated, R0 resection | Olaparib + bevacizumab maintenance | ↑ PFS significantly | **High-Yield:** Bevacizumab (anti-VEGF) is now standard maintenance in advanced ovarian cancer after chemotherapy, improving progression-free survival by 3–4 months. ## Management Algorithm ```mermaid flowchart TD A[Stage III/IV ovarian cancer, R0 after NACT]:::outcome --> B[Complete 6 cycles total platinum-based chemo]:::action B --> C{BRCA mutation status?}:::decision C -->|BRCA-mutated| D[Olaparib + bevacizumab maintenance]:::action C -->|BRCA wild-type| E[Bevacizumab maintenance]:::action D --> F[Continue until progression]:::action E --> F F --> G[Monitor CA-125, imaging q3mo]:::action ``` **Clinical Pearl:** The patient has already received 6 cycles of NACT. Interval debulking surgery does not reset the chemotherapy count — she still needs 3 more cycles of the same regimen to complete the standard 6-cycle course, followed by bevacizumab. ## Why Not Observation Alone? Observation without maintenance therapy is suboptimal and increases relapse risk. Bevacizumab maintenance has proven PFS benefit and is now standard of care. ## Why Not Bevacizumab Monotherapy? Bevacizumab alone (without completing chemotherapy) is not standard. The patient requires 3 additional cycles of platinum-based chemotherapy to complete the 6-cycle course, then bevacizumab maintenance. [cite:Berek & Hacker's Gynecologic Oncology 6e Ch 10; NCCN Ovarian Cancer Guidelines 2024]